CONMED Corp
CNMDNYSE
$43.20
↓ -4.0%Jul 17 close · end-of-day
Price
1Y↓ -13.2%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$1.3B
Enterprise Value
$2.2B
P/E
28.6
P/S
1.0
P/B
1.3
EV/EBITDA
18.2
PEG
—
FCF Yield
11.2%
Dividend Yield
1.4%
Revenue (TTM)
$1.4B
Net Income (TTM)
$47.1M
Free Cash Flow (TTM)
$150.9M
Gross Margin
54.6%
Operating Margin
7.5%
Net Margin
3.4%
ROE
4.6%
ROIC
3.6%
Debt / Equity
0.8
Net Cash
-$834.9M
Return 1Y
-11.9%
Company profile
CONMED Corporation develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. It offers orthopedic surgery products, including TruShot with Y-Knot All-In-One Soft Tissue Fixation System. The company markets its products under the Hall, CONMED Linvatec, Concept and Shutt brands.
- CEO
- Curt R. Hartman
- Sector
- Manufacturing
- Industry
- Medical Equipment
- Employees
- 4,100
- Headquarters
- Florida
- Website
- conmed.com
Management & directors
- Lalomia BrentExecutive VP RA, QA
- Glaze RichardChief Information Officer
- Garner Todd W.Executive Vice President & CFO
- Foust Hollie KGeneral Counsel & Corp Sec
Roles derived from SEC Form 4 filings.
Earnings
CNMD Q4 2025 Earnings
Period ends 2025-12-31
MetricActualYoY
Revenue$373.2M↑ +7.9%
Diluted EPS$0.54↓ -50.5%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $862.5M | $1.0B | $1.0B | $1.2B | $1.3B | $1.4B |
| Gross profit | $460.3M | $568.0M | $571.2M | $676.2M | $733.0M | $750.5M |
| Operating income | $46.0M | $109.7M | $70.1M | $120.6M | $200.3M | $102.6M |
| Net income | $9.5M | $62.5M | -$80.6M | $64.5M | $132.4M | $47.1M |
| Diluted EPS | $0.32 | $1.94 | -$2.68 | $2.04 | $4.25 | $1.51 |
| Operating cash flow | $64.5M | $111.8M | $33.4M | $125.3M | $167.0M | $170.7M |
| Free cash flow | $51.5M | $96.9M | $11.6M | $106.3M | $153.9M | $150.9M |
| Gross margin | 53.4% | 56.2% | 54.6% | 54.3% | 56.1% | 54.6% |
| Operating margin | 5.3% | 10.9% | 6.7% | 9.7% | 15.3% | 7.5% |
| Net margin | 1.1% | 6.2% | -7.7% | 5.2% | 10.1% | 3.4% |
| Line item | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $312.3M | $332.1M | $316.7M | $345.9M | $321.3M | $342.3M | $337.9M | $373.2M |
| Gross profit | $172.0M | $183.7M | $179.0M | $198.3M | $177.8M | $188.3M | $166.1M | $218.3M |
| Operating income | $35.0M | $47.1M | $65.7M | $52.5M | $16.0M | $38.2M | $11.9M | $36.6M |
| Net income | $19.7M | $30.0M | $49.0M | $33.7M | $6.0M | $21.4M | $2.9M | $16.8M |
| Diluted EPS | $0.63 | $0.96 | $1.57 | $1.09 | $0.19 | $0.69 | $0.09 | $0.54 |
| Operating cash flow | $29.1M | $43.3M | $51.2M | $43.3M | $41.5M | $29.1M | $53.7M | $46.3M |
| Free cash flow | $27.1M | $39.7M | $47.8M | $39.3M | $37.8M | $23.4M | $48.5M | $41.2M |
| Gross margin | 55.1% | 55.3% | 56.5% | 57.3% | 55.3% | 55.0% | 49.2% | 58.5% |
| Operating margin | 11.2% | 14.2% | 20.7% | 15.2% | 5.0% | 11.1% | 3.5% | 9.8% |
| Net margin | 6.3% | 9.0% | 15.5% | 9.8% | 1.9% | 6.3% | 0.8% | 4.5% |
Company news
Jul 20, 2026
Jul 13, 2026
- 6d agoCONMED (CNMD) Stock Trades Up, Here Is Whyfinance.yahoo.com
- 6d agoConmed Surges Within Striking Distance Of A Breakout On Buyout Rumorsfinance.yahoo.com
- 6d agoWhy This Medical Technology Stock Is Up 10%finance.yahoo.com
- 7d agoSector Update: Healthcare Stocks Advance Late Afternoonfinance.yahoo.com
- 7d agoCNMD Stock Hits Highest Level In Over Four Months – Why JPMorgan Believes Firm Would Be Highly Attractive To ‘Financial Acquirers’stocktwits.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-02 | Council LaVerne H | Option exercise | 668 | $0.00 | $0.00 | filing |
| 2026-06-02 | Farkas Charles | Option exercise | 668 | $0.00 | $0.00 | filing |
| 2026-06-02 | Kaye Mark | Option exercise | 668 | $0.00 | $0.00 | filing |
| 2026-06-02 | Schwarzentraub Barbara J | Option exercise | 668 | $0.00 | $0.00 | filing |
| 2026-06-02 | BRONSON DAVID M | Option exercise | 668 | $0.00 | $0.00 | filing |
| 2026-03-06 | Lalomia Brent· Executive VP RA, QA | Tax withholding | 26 | $39.90 | $1,037.40 | filing |
| 2026-03-06 | Lalomia Brent· Executive VP RA, QA | Option exercise | 75 | $0.00 | $0.00 | filing |
| 2026-02-24 | Kaye Mark | Option exercise | 152 | $0.00 | $0.00 | filing |
| 2025-11-21 | Glaze Richard· Chief Information Officer | Sale | 257 | $41.21 | $10,590.97 | filing |
| 2025-11-20 | Glaze Richard· Chief Information Officer | Tax withholding | 118 | $40.63 | $4,794.34 | filing |
| 2025-11-20 | Glaze Richard· Chief Information Officer | Option exercise | 375 | $0.00 | $0.00 | filing |
| 2025-11-06 | Garner Todd W.· Executive Vice President & CFO | Sale | 3,500 | $43.00 | $150,500.00 | filing |
| 2025-11-04 | Foust Hollie K· General Counsel & Corp Sec | Tax withholding | 1,114 | $45.71 | $50,920.94 | filing |
| 2025-11-04 | Foust Hollie K· General Counsel & Corp Sec | Option exercise | 4,000 | $0.00 | $0.00 | filing |
| 2025-10-31 | Garner Todd W.· Executive Vice President & CFO | Tax withholding | 2,164 | $44.00 | $95,216.00 | filing |
| 2025-10-31 | Garner Todd W.· Executive Vice President & CFO | Option exercise | 7,500 | $0.00 | $0.00 | filing |
| 2025-09-12 | Farkas Charles | Sale | 1,103 | $53.54 | $59,049.11 | filing |
| 2025-09-12 | Farkas Charles | Sale | 897 | $53.51 | $48,000.26 | filing |
| 2025-08-07 | Garner Todd W.· Executive Vice President & CFO | Sale | 598 | $52.45 | $31,365.10 | filing |
Latest 19 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.